Abstract
Background Antenatal anaemia is a significant global health problem, affecting 48% of pregnant women in South Asia. The standard of care in Bangladesh is oral iron and folic acid supplementation. However, access and adherence to oral iron supplementation are subpar. An alternative treatment available to address antenatal anaemia is intravenous (IV) iron. Modern IV iron products are routinely used in high-income clinical settings, including primary and secondary care, to deliver a high dose of iron in a single short infusion. A demonstration project will be conducted to test the real-world feasibility and acceptability of implementing an IV iron intervention to treat pregnant women with moderate and severe anaemia in the primary healthcare setting of Bangladesh. In this protocol paper, we describe the implementation research program that will guide the development, implementation, and evaluation of an IV iron intervention in real-world settings.
Methods We will use implementation science frameworks to guide the demonstration project. The implementation research program includes three phases: 1) a formative phase in preparation for the implementation of an IV iron intervention involving a review, qualitative research, and readiness assessment; 2) the development and implementation of IV iron intervention care pathways and strategies to support the uptake and delivery of the intervention using a participatory research approach; and 3) a process evaluation of IV iron intervention care pathways and strategies involving qualitative and quantitative assessment of the costs, processes and contextual factors affecting its implementation.
Discussion Modern IV iron products present a novel opportunity to reduce the disproportionate burden of antenatal anaemia in low-and-middle income countries (LMICs). The demonstration project will ascertain whether an IV iron intervention can be effectively introduced into routine antenatal care in Bangladesh. The extent to which it is considered an acceptable treatment by pregnant women with moderate or severe anaemia receiving the intervention, healthcare providers delivering the intervention, and policymakers will be determined. If successful, understanding how an IV iron intervention will be implemented across several care pathways and its associated costs will inform the scalability of an IV iron intervention in the primary healthcare system of Bangladesh and provide implementation guidance in other LMICs.
Contributions to the literature
Modern IV iron products can quickly restore iron levels, offering a new opportunity to address antenatal anaemia in LMICs.
The demonstration project in Bangladesh will involve pregnant women, local communities, and healthcare workers to co-design anaemia care pathways and strategies for implementing an IV iron program in primary care.
The demonstration project provides access to an alternative treatment, trains healthcare workers, and builds local capacity for anaemia management.
Testing and refining anaemia care pathways and strategies in a real-world setting will offer insights for scaling and adapting these approaches to other regions or population, creating a template for similar initiatives.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This is a demonstration project, not an RCT but was registered: ACTRN12623001163695
Funding Statement
This research program is supported by the Gates Foundation (INV-017316). The opinions expressed in this work are those of the authors alone and shall not be attributed to the Gates Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for the demonstration project was obtained from the Research and Ethical Review Committee of icddr,b (PR-20125) and WEHI (21/5).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Abbreviations
- AIM
- Acceptability of Intervention Measure
- CFIR
- Consolidated Framework for Implementation Research
- DGDA
- Directorate General of Drug Administration
- DGFP
- Directorate General of Family Planning
- DGHS
- Directorate General of Health Services
- EDIVA
- Efficacy and Demonstration of IntraVenous Iron for Anaemia in pregnancy
- FBC
- Full blood count
- FCM
- Ferric carboxymaltose
- FIM
- Feasibility of Intervention Measure
- HIC
- High-income countries
- Hb
- hemoglobin
- IAM
- Intervention Appropriateness Measure
- IFA
- Iron and folic acid
- IV
- Intravenous
- LMIC
- Low- and middle-income countries
- MRC
- Medical Research Council
- RCT
- Randomised controlled trial
- WHO
- World Health Organization
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.